Our early data, 48 hours after opening pre-orders, suggests the pill is already reaching groups that carry a significant burden of obesity-related ill health but have historically been least likely to seek treatment: Adults in their 60s are buying the Wegovy pill at a rate 50% higher than they ever chose injectable treatment Adults in their 50s are the single largest group of pill buyers, accounting for 35% of total order volume, a third higher than their share of injectable orders Men are purchasing the pill at a rate 25% higher than they chose injectable treatment - significant for a group historically far less likely to seek weight loss medication at all Positive patient outcomes will have compounding benefits across the national healthcare system
Tell them how long your progress has stalled, what changes you have already tried, and ask whether a dose adjustment, a lifestyle modification, or a safer medication alternative is appropriate for you to break the plateau
Testing for genetic variants in peptide pathwayssuch as FTO rs9939609, and MC4R rs17782313can help providers contextualize metabolic risk beyond phenotype alone
For some people, this broader hormonal engagement translates to stronger appetite suppression and greater metabolic response
Continuous support through in-person or virtual visits